文献速递临床免疫分子诊断

检测噬血细胞性淋巴组织细胞增生症患者血清抗IL-2和可溶性CD25 IgG抗体的蛋白生物芯片的建立

Establishment of a protein biochip to detect serum IgG antibodies against IL-2 and soluble CD25 in hemophagocytic lymphohistiocytosis.
PubMed 文献 · Clin Chim Acta · 2018-10-05

本研究开发了一种经半胱氨酸和活化槐糖脂修饰的蛋白生物芯片,用于检测噬血细胞性淋巴组织细胞增生症(HLH)患者血清中抗IL-2和可溶性CD25(sCD25)的IgG抗体。芯片对IL-2和sCD25的检测限分别为78 pg/ml和39 pg/ml;血清学反应率分别为20.8%和83.1%,抗体血清阳性率分别为45.5%和57.2%,sCD25抗原-抗体复合物血清阳性率为68.8%。该芯片检测血清sCD25的敏感性和特异性与化学发光免疫分析(CLIA)相似。

要点

  • 新型蛋白生物芯片可检测HLH患者血清抗IL-2和sCD25的IgG抗体。
  • 芯片检测sCD25的敏感性和特异性与CLIA相似。
  • HLH患者中存在抗IL-2、sCD25 IgG抗体及sCD25抗原-抗体复合物。

核心结论

  • 研究证实HLH患者血清中存在抗IL-2和sCD25的IgG抗体以及sCD25抗原-抗体复合物,该生物芯片平台有望成为HLH临床血清学诊断的新技术替代。

研究设计与样本

  • 开发了一种经半胱氨酸和活化槐糖脂(Cys-SL)修饰的新型蛋白生物芯片,用于检测血清抗IL-2和sCD25的IgG抗体。

主要发现

  • 芯片对IL-2和sCD25的检测限分别为78 pg/ml和39 pg/ml。
  • 芯片上对IL-2和sCD25蛋白的血清免疫反应率分别为20.8%和83.1%。
  • 抗IL-2和sCD25 IgG抗体的血清阳性率分别为45.5%和57.2%。
  • sCD25血清抗原-抗体复合物的血清阳性率为68.8%。
  • 芯片检测血清sCD25的敏感性和特异性与化学发光免疫分析(CLIA)相似。

临床怎么用

  • 该生物芯片平台可用于HLH的临床血清学诊断,作为现有检测技术的潜在替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interleukin-2 (IL-2) and soluble CD25 (sCD25) are among the most important cytokines and diagnostic biomarkers in hemophagocytic lymphohistiocytosis (HLH). Detecting serum level of IL-2 and sCD25 is valuable for making clinical diagnosis and treatment decision in HLH. METHODS: Since tests showing serum IgG antibody against IL-2 or sCD25 have never been carried out, a new protein biochip, which was modified with cysteine and activated sophorolipid (Cys-SL), was developed. RESULTS: Limits of detection on the biochip were 78 pg/ml for IL-2 and 39 pg/ml for sCD25, respectively. The data showed that on-chip seroimmunological responses to IL-2 and sCD25 proteins were 20.8% and 83.1% and the seroprevalence of IL-2 and sCD25 IgG antibodies were 45.5% and 57.2%, respectively. Data collection for the seroprevalence of serum antigen-antibody complex of sCD25 was 68.8%. The new biochip model shared similar sensitivity and specificity to chemiluminescent immunoassay (CLIA) in its measuring capacity of serum sCD25. CONCLUSIONS: We addressed and confirmed the involvement of serum IgG antibodies against IL-2 and sCD25 as well as Ag-Ab complex of sCD25 in HLH patients. Therefore, this biochip platform would offer a new technological substitution for clinical serological diagnosis of HLH.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Liu Q, Liu SS, Li SG, et al. Establishment of a protein biochip to detect serum IgG antibodies against IL-2 and soluble CD25 in hemophagocytic lymphohistiocytosis. Clin Chim Acta. 2018. PMID: 30292629. doi:10.1016/j.cca.2018.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。